Wayne Winegarden, PhD, talked about the issues and benefits of the FDA's switch to a biologics regulatory pathway for certain products, especially insulin, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
Wayne Winegarden, PhD, is a senior fellow in business and economics as well as the director for the Center for Medical Economics and Innovation at the Pacific Research Institute in San Francisco, California.
Transcript:
Please explain the significance of the regulatory change to the BPCIA.
It's been 10 years since the [Biologics Price Competition and Innovation Act] BPCIA has passed, and what that meant was the biologics that had come out previously--insulin would be the most important one--were regulated under the FDA small chemical market, and now they're going to be migrating and transferring over to the [biologics license application] BLA. From my perspective, I think there's logic to making the transfer. How that was done was very disconcerting, because it created this dead zone, is how it's been referred to. It was [maybe] 10 or 12 months--people can debate that, but it was a substantial period where you disincentivized competition, because if you had--let's say, for insulin--if you had submitted some type of [application for] a new biosimilar, whatever it would have been, for insulin, and you didn't get it finished prior to the transfer on March 23, well, it's lost, and you'd have to go through that whole process all over again. And it's really too costly. So, what it basically encouraged people to do is shut down any type of innovation to any type of competitor [products] for a very substantial period of time. My guess is it's been at least a year, if not longer. Whatever it's been, hopefully that's coming to an end soon as we transfer over, but we've certainly, I think, paid a price in terms of [no increase in] competition...all that progress has been shut down. That's a real loss to patients, and hopefully, that's coming to an end.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.